Treatment of androgen-independent prostate cancer with dexamethasone: A prospective study in stage D2 patients

Takashi Saika, Nobuyuki Kusaka, Tomoyasu Tsushima, Toyoko Yamato, Teruhisa Ohashi, Bunzo Suyama, Ryoji Arata, Yasutomo Nasu, Hiromi Kumon

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)


Purpose: In order to evaluate the efficacy of dexamethasone in the treatment of Japanese men with androgen-independent prostate cancer, a prospective study was conducted using prostate-specific antigen (PSA) as a primary end-point. Methods: Nineteen Japanese men with stage D2 androgen-independent prostate cancer were registered and treatment was started. After ruling out anti-androgen withdrawal syndrome, they were treated with dexamethasone (1.5 mg daily). Patients were monitored for PSA, symptoms, radiologic response, survival rate, time to disease progression, time to treatment failure and complications. Results: Prostate-specific antigen levels decreased in nine patients (50.0%); five (27.8%) showed a 50% or greater decrease and two (11.1%) showed an 80% or greater decrease. For the nine patients, the mean duration of PSA response was 7.3 months and the median duration was 2.1 months (range, 1.2-27.5+). Bone pain, which was noted in 13 patients at study entry, improved in seven patients (53.8%). Of nine patients who had serial radiographic examinations with bone scan, three (33%) showed partial response, two (22%) were stable and four (44%) showed disease progression. Treatment was well tolerated, except for one patient who suffered a severe pulmonary infection. Conclusion: Dexamethasone decreased PSA levels and produced subjective symptomatic improvement in the patients with stage D2 androgen-independent prostate cancer.

Original languageEnglish
Pages (from-to)290-294
Number of pages5
JournalInternational Journal of Urology
Issue number6
Publication statusPublished - 2001


  • Androgen-independent prostate cancer
  • Dexamethasone

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Treatment of androgen-independent prostate cancer with dexamethasone: A prospective study in stage D2 patients'. Together they form a unique fingerprint.

Cite this